Compare AbbVie Inc (ABBV) vs Enbridge Inc (ENB) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

ENB trades at $51.28, down 0.81% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.46, beating estimates, and maintains a strong dividend track record with recent payouts of $0.97. Revenue grew to $65.19B in 2025, with a net income margin of 7.34%, though debt levels have increased.

Outlook is mixed; analyst consensus is evenly split between Buy and Hold, with a 48% Buy rating. Key opportunities include a $41B project backlog and consistent dividend growth, while risks involve high debt, regulatory challenges, and volatile cash flows. The stock's valuation appears reasonable with a P/E of 27.74.